Net income · 2020–2025
Monte Rosa Therapeutics net income
−$38.6M+$34.1M · FY2025
Monte Rosa Therapeutics (GLUE) reported −$38.6M in net income for fiscal 2025, +$34.1M from the year before.
Net income — Net income is profit after tax and all expenses, as reported in the annual filing. Companies reporting a loss are excluded from this ranking.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026
Net income at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Monte Rosa Therapeutics net income |url=https://companiesranked.com/en/company/monte-rosa-therapeutics/net-income |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Monte Rosa Therapeutics net income. CompaniesRanked. https://companiesranked.com/en/company/monte-rosa-therapeutics/net-incomeBibTeX
@misc{companiesranked-en-company-monte-rosa-therapeutics-net-income-2026,
author = {{CompaniesRanked}},
title = {{Monte Rosa Therapeutics net income}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/monte-rosa-therapeutics/net-income}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-Q · 0001193125-26-336711 · August 6, 2026
{{cite web |title=Monte Rosa Therapeutics net income — 10-Q (0001193125-26-336711) |url=https://www.sec.gov/Archives/edgar/data/1826457/000119312526336711/glue-20260630.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-08-06}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.